Thelansis

 Guillain-Barre Syndrome (GBS) is a type of acute paralytic neuropathy that is both common and severe. Typically involves progressive limb weakness accompanied by decreased or absent reflexes. However, some patients experience localized weakness or other symptoms, such as facial diplegia or paraesthesia. GBS is also associated with several other disorders, such as Miller-Fisher syndrome and Bickerstaff brainstem encephalitis. These conditions can share similar biomarkers but present with different clinical features. GBS can be broadly classified into two types: acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN), based on the site of the target antigen. The underlying mechanisms of GBS involve both innate and adaptive immunity. Innate immunity is associated with dendritic cells, complement fractions, mast cells, and specific toll-like receptors. Adaptive immunity is characterized by IL17 and IL22 secretion, anomalies in CD4(+)CD25...

  Guillain-Barre syndrome (GBS) is a rare neurological disorder in which the body's immune system attacks its peripheral nervous system by mistake—the network of nerves located outside the brain and spinal cord. An infection often precedes Guillain-Barré syndrome. This could be a bacterial or viral infection. GBS may also be triggered by vaccine administration or surgery. In the context of Zika virus infection, an unexpected increase in cases of Guillain-Barré syndrome has been described in affected countries. The most likely explanation of evidence from outbreaks of Zika virus infection and Guillain-Barre syndrome is that Zika virus infection triggers GBS. The prevalence of Guillain-Barre syndrome is estimated to be 6 to 40 cases per 1 million people. AMAN and AMSAN together account for 30 to 50 percent of cases in Asian countries and Latin America but only 3 to 5 percent of cases in North America and Europe. Thelansis’s “Guillain-Barre Syndrome (GBS) Market O...